Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel

Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2 Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This retrospective cohort study aimed to describe characteristics of patients offered COVID-19 antiviral treatment in Maccabi Healthcare...

Descripción completa

Detalles Bibliográficos
Autores principales: Weil, Clara, Bergroth, Tobias, Eisenberg, Anna, Whiteside, Yohance Omar, Caraco, Yoseph, Tene, Lilac, Chodick, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443270/
https://www.ncbi.nlm.nih.gov/pubmed/37606468
http://dx.doi.org/10.3390/epidemiologia4030031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443270/
https://www.ncbi.nlm.nih.gov/pubmed/37606468
http://dx.doi.org/10.3390/epidemiologia4030031

Ejemplares similares